

## Erratum



## OPEN ACCESS

**Received:** Mar 10, 2024

**Revised:** May 30, 2024

**Accepted:** Jun 19, 2024

**Published online:** Nov 5, 2024

### Correspondence to

#### Masaaki Mori

Department of Lifetime Clinical Immunology,  
Graduate School of Medical and Dental  
Sciences, Tokyo Medical and Dental University,  
1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519,  
Japan.  
Email: mori.phv@tmd.ac.jp

<sup>†</sup>Current affiliation (concurrent): Division of  
Rheumatology and Allergy, Department  
of Internal Medicine, St. Marianna University  
School of Medicine, Kawasaki, Japan.

Copyright © 2024 by The Korean Society of  
Pediatric Gastroenterology, Hepatology and  
Nutrition















This is an open-access article distributed  
under the terms of the Creative Commons  
Attribution Non-Commercial License ([https://  
creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/))  
which permits unrestricted non-commercial  
use, distribution, and reproduction in any  
medium, provided the original work is properly  
cited.

### ORCID iDs

Masaaki Mori   
<https://orcid.org/0000-0003-2130-4866>  
Yoshiko Nakayama   
<https://orcid.org/0000-0003-1992-6834>  
Shigeo Nishimata   
<https://orcid.org/0000-0001-6347-2791>  
Tadafumi Yokoyama   
<https://orcid.org/0000-0002-7767-3698>  
Ryo Matsuoka   
<https://orcid.org/0000-0002-2317-5845>

<https://pghn.org>

# Correction: Efficacy and Safety of Long-Term Administration of Esomeprazole in Japanese Pediatric Patients Aged 1–14 Years with Chronic Gastric Acid-Related Disease

Masaaki Mori <sup>1,†</sup>, Yoshiko Nakayama <sup>2</sup>, Shigeo Nishimata <sup>3</sup>,  
Tadafumi Yokoyama <sup>4</sup>, Ryo Matsuoka <sup>5</sup>, Reiko Hatori <sup>6</sup>, Masaki Shimizu <sup>7</sup>,  
Katsuhiro Arai <sup>8</sup>, Yuri Etani <sup>9</sup>, Tsuyoshi Sogo <sup>10</sup>, Tomoko Ishizu <sup>11</sup>,  
Masahiro Nii <sup>12</sup>, Ryosuke Nakashima <sup>12</sup> and Toshiaki Shimizu <sup>13</sup>

<sup>1</sup>Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

<sup>2</sup>School of Health Science, Shinshu University School of Medicine, Matsumoto, Japan

<sup>3</sup>Department of Pediatrics and Adolescent Medicine, Tokyo Medical University, Tokyo, Japan

<sup>4</sup>Department of Pediatrics, Kanazawa University, Kanazawa, Japan

<sup>5</sup>Department of Pediatrics, Fuji City General Hospital, Shizuoka, Japan

<sup>6</sup>Center of Regional Medical Research and Education, Gunma University Hospital, Maebashi, Japan

<sup>7</sup>Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

<sup>8</sup>Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan

<sup>9</sup>Department of Pediatric Gastroenterology, Nutrition and Endocrinology, Osaka Women's and Children's Hospital, Osaka, Japan

<sup>10</sup>Department of Pediatric Hepatology and Gastroenterology, Saiseikai Yokohama City Tobu Hospital, Yokohama, Kanagawa, Japan

<sup>11</sup>Research and Development, AstraZeneca, Tokyo, Japan

<sup>12</sup>Research and Development, AstraZeneca, Osaka, Japan

<sup>13</sup>Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan

► This corrects the article “Efficacy and Safety of Long-Term Administration of Esomeprazole in Japanese Pediatric Patients Aged 1–14 Years with Chronic Gastric Acid-Related Disease” in volume 27 on page 274.

Pediatr Gastroenterol Hepatol Nutr. 2024 Sep;27(5):274-285  
<https://doi.org/10.5223/pghn.2024.27.5.274>

On page 275 of this article, the Conflict of Interest statement was incorrect. The authors would like to correct the Conflict of Interest statement as follows.

### Before:

The authors have no financial conflicts of interest.

### After:

Masaaki Mori has received consulting fees from Daiichi Sankyo, Ltd. and Taisho Pharmaceutical, Co., Ltd.; and belongs to an institution that has received funding from Chugai Pharmaceutical Co., Ltd., Ayumi Pharmaceutical Corporation, UCB Japan Co., Ltd., Nippon Kayaku Co., Ltd., CSL Behring Corporate, Asahi Kasei Pharma Corporation,

Reiko Hatori   
<https://orcid.org/0000-0002-8110-3882>  
Masaki Shimizu   
<https://orcid.org/0000-0003-1077-7772>  
Katsuhiro Arai   
<https://orcid.org/0000-0002-6440-4640>  
Yuri Etani   
<https://orcid.org/0000-0003-3005-4707>  
Tsuyoshi Sogo   
<https://orcid.org/0000-0001-8986-1699>  
Tomoko Ishizu   
<https://orcid.org/0009-0004-9385-2321>  
Masahiro Nii   
<https://orcid.org/0009-0001-8271-188X>  
Ryosuke Nakashima   
<https://orcid.org/0009-0002-4294-773X>  
Toshiaki Shimizu   
<https://orcid.org/0000-0003-0364-0022>

#### Funding

This research was funded by AstraZeneca.

#### Conflict of Interest

Masaaki Mori has received consulting fees from Daiichi Sankyo, Ltd. and Taisho Pharmaceutical, Co., Ltd.; and belongs to an institution that has received funding from Chugai Pharmaceutical Co., Ltd., Ayumi Pharmaceutical Corporation, UCB Japan Co., Ltd., Nippon Kayaku Co., Ltd., CSL Behring Corporate, Asahi Kasei Pharma Corporation, AbbVie GK, and Japan Blood Products Organization. Yoshiko Nakayama has received lecture fees from AstraZeneca. Shigeo Nishimata, Tadafumi Yokoyama, Ryo Matsuoka, Reiko Hatori, Masaki Shimizu, Yuri Etani, and Tsuyoshi Sogo have no conflicts of interest to disclose. Katsuhiro Arai has received payments or honoraria from Takeda Pharmaceutical Co., Ltd. and EA Pharma Co., Ltd.; and belongs to an institution that has received grants or contracts from AstraZeneca, Takeda Pharmaceutical Co., Ltd., and EA Pharma Co., Ltd.; and consulting fees from EA Pharma Co., Ltd. Tomoko Ishizu, Masahiro Nii, and Ryosuke Nakashima are employees of AstraZeneca and hold stock options in AstraZeneca. Toshiaki Shimizu has received research grants from JCR Pharmaceuticals Co., Ltd. and The Food Science Institute Foundation (Ryoshoku-kenkyukai; Tokyo, Japan).

AbbVie GK, and Japan Blood Products Organization. Yoshiko Nakayama has received lecture fees from AstraZeneca. Shigeo Nishimata, Tadafumi Yokoyama, Ryo Matsuoka, Reiko Hatori, Masaki Shimizu, Yuri Etani, and Tsuyoshi Sogo have no conflicts of interest to disclose. Katsuhiro Arai has received payments or honoraria from Takeda Pharmaceutical Co., Ltd. and EA Pharma Co., Ltd.; and belongs to an institution that has received grants or contracts from AstraZeneca, Takeda Pharmaceutical Co., Ltd., and EA Pharma Co., Ltd.; and consulting fees from EA Pharma Co., Ltd. Tomoko Ishizu, Masahiro Nii, and Ryosuke Nakashima are employees of AstraZeneca and hold stock options in AstraZeneca. Toshiaki Shimizu has received research grants from JCR Pharmaceuticals Co., Ltd. and The Food Science Institute Foundation (Ryoshoku-kenkyukai; Tokyo, Japan).

The authors would like to apologise for any inconvenience caused.